Source comparison
Is MOTS-c FDA Approved Status: Regulatory Comparison
This table clarifies where MOTS-c sits relative to other peptides and compounds researchers commonly encounter. MOTS-c Not FDA approved No clinical trials initiated None. Investigational only Yes, research-grade from licensed suppliers Promising preclinical da
This comparison does not assign a generated winner or score.
- This table clarifies where MOTS-c sits relative to other peptides and compounds researchers commonly encounter.
- MOTS-c
- Not FDA approved
- No clinical trials initiated
- None. Investigational only
- Yes, research-grade from licensed suppliers
- Promising preclinical data, no human safety profile established
- Semaglutide (Ozempic, Wegovy)
- FDA approved
- Phase III completed
- Type 2 diabetes, chronic weight management
- Prescription only, not available for independent research
- Established safety and efficacy in large randomized controlled trials
- BPC-157
- Limited Phase I/II (non-USA)
- None in USA
- Yes, research-grade
- Widely studied in animal models, minimal human trial data
- Metformin
- Type 2 diabetes
- Prescription medication, research use requires IRB approval
- Decades of clinical use, well-characterized safety profile
- Epithalon
- No clinical trials in FDA database
- None
- Preclinical anti-aging research, no human pharmacokinetic data
- Tirzepatide (Mounjaro)
- Prescription only
- Dual GIP/GLP-1 agonist with robust clinical evidence
- The MOTS-c FDA approved status remains firmly in the 'not approved' column. It shares regulatory classification with research peptides like BPC 157 Peptide, not with clinically validated drugs like semaglutide or metformin. Researchers comparing mitochondrial interventions across experimental models can access MOTS-c for those purposes, but the peptide's lack of FDA approval means it cannot be administered to human subjects outside of an approved clinical trial conducted under an IND application.